Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Liposomes
Patent
1998-02-02
1999-10-12
Kishore, Gollamudi S.
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Liposomes
4284022, A61K 9127
Patent
active
059651598
ABSTRACT:
Described herein are liposomes containing etherlipids of the formula: ##STR1## as well as a phosphatidylcholine, a sterol, and a headgroup-derivatized lipid. These liposomes are useful in a variety of therapeutic regimens, including the treatment of cancers and inflammatory disorders.
REFERENCES:
patent: 3752886 (1973-08-01), Munder et al.
patent: 4159988 (1979-07-01), Eibl et al.
patent: 4163748 (1979-08-01), Eibl et al.
patent: 4382035 (1983-05-01), Eibl
patent: 4734225 (1988-03-01), Eibl
patent: 4804789 (1989-02-01), Eibl
patent: 4920016 (1990-04-01), Allen et al.
patent: 4965391 (1990-10-01), Counsell et al.
patent: 4983397 (1991-01-01), Schroit et al.
patent: 5013556 (1991-05-01), Woodle et al.
patent: 5436234 (1995-07-01), Eibl
patent: 5762958 (1998-06-01), Mayhew
Bazill, et al., "Role of Endocytosis in the Action of Ether Lipids on WEHI-3B, HL60, and FEDCP-Mix A4 Cells", Cancer Res. 50: 7505 (1990).
Berdel, "Membrane-interactive lipids as experimental anticancer drugs", Br. J. Cancer 64: 208 (1991).
Berdel, "Ether Lipids and Derivatives as Investigational Anticancer Drugs", Onkologie 13: 245 (1990).
Bhatia, et al., "Sterospecific Systhesis of Antitumor Active Thioether PAF Analogs", Lipids 26(12): 1424 (1991).
Blume et al, "Specific targeting with poly(ethylene glycol)-Modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times" Biochim. Biophys. Acta. 1149: 180-184 (1993).
Daicho, et al., "Effects of alkyl glycosides incorporated into liposomes prepared from synthetic amphiphiles on their tissue distribution in Ehrlich solid tumor-bearing mice", BBA, 1107:61 (1992).
Darnell et al., Molecular Cell Biology, Scientific American Books, Inc. (1986), New York, pp. 573-575.
Deamer and Uster, "Liposome Preparation: Methods and Mechanisms," in: Liposomes (M. Ostro, ed.), Marcel Dekker, Inc., New York (1983), pp. 27-52.
Dietzfelbinger et al., "Removal of Breast Cancer Cells from Bone Marrow by in Vitro Purging with Ether Lipids and Cryopreservation", Cancer Res. 53: 3747 (1993).
Dive, et al., "Multiparametric Flow Cytometry of the Modulation of Tumore Cell Membrane Permeability by Developmental Antitumore Ether Lipid SRI 62-834 in EMT6 Mouse Mammary Tumor and HL-60 Human Promyelocytic Leukemia Cells", Cancer Res., 51:799 (1991).
Gabizon et al., "Prolongation of Circulation Time of Doxorubicin Encapsulated in Liposomes Containing a Polyethylene Glycol-Derivatized Phospholipid: Pharmacokinetic Studies in Rodents and Dogs", Pharm. Res. 10(5): 703 (1993).
Kaufmann-Kolle, et al., "Liposomal Hexadecylphosphocholine (HEPC): in Vitro and in Vivo Application", Chemical Abs. V4, 10.08.
Layton et al., "The Interaction of Liposomes with Cells: The Relation of Cell Specific Toxicity to Lipid Composition", Eur. J. Cancer 16: 64 (1980).
Lewis and McElhaney, "The Mesomorphic Phase Behavior of Lipid Bilayers," in The Structure of Biological Membranes (P. Yeagle, ed.), CRC Press, Inc. (1992), Boca Raton, Fl., pp. 73-155, at pp. 123-126.
Muschiol et al., "Alkyl Phosphocholine: Toxicity and Anticancer Properties", Lipids 22(11): 930 (1987).
Nairn, in: Remington's Pharmaceutical Science (A. Gennaro, ed.), Mack Publishing Co., Easton, PA, (1985), pp. 1492-1517.
Park et al., "Some negatively charged phopholipid derivatives prolong the liposome circulation in vivo", Biochim. Biophys. Acta. 1108: 257 (1992).
Powis et al., "Selective Inhibition of Phophatidylinositol Phospholipase C by Cytotoxic Ether Lipid Analogues", Cancer Res. 52: 2835 (1992).
Powis et al., "The Cell Membrane and Cell Signals as Targets in Cancer Chemotherapy", Cancer Res. 50:2203 (1990).
Reed et al., "Antineoplastic Ether-linked Phopholipid induces differentiation of acute myelogenous leukemic KG-1 cells into marcophase-like cells", Life Sci. 49: 1221 (1991).
Runge et al., "Destruction of Human Solid Tumors by Alkyl Lysophopholipids", JNCI. 64(6): 1301 (1980).
Tritton, et al., "How to Kill Cancer Cells: Membranes and Cell Signaling as Targets in Cancer Chemotherapy", Cancer Cells 2(4): 95 (1990).
Workman, "Antitumor Ether Lipids: Endocytosis as a Determinant of Cellular Sensitivity", Cancer Cells 3(8): 315 (1991).
Workman et al., "Plastelet-activating factor (PAF) antagonist WEB 2086 does not modulate the cytotoxicity of PAF or antitumour alkyl lysophospholipids ET-18-O-Methyl and SRIU 62-834 in HL-60 promyelocytic leukaemia cells", Biochem. Pharmacol. 41(2): 319 (1991).
Zeisig et al., "Antineoplastic activity in vitro of free and liposomal alkylphophocholines", Anti-Cancer Drugs 4: 57 (1993).
Kuchera AIDS Res. & Human Retroviruses. 6 #4. p. 491, 1990.
Baker. Int. J. Immunopharm. 13 #4 p. 385, 1991.
Mende. Chem Abstracts. 119 (23) 205219 g.
Zalipsky. FEBS Letters. 353, p. 71-74, 1994.
Ahmad Imran
Bhatia Suresh K.
Janoff Andrew S.
Mayhew Eric
Goodman Rosanne
Kishore Gollamudi S.
The Liposome Company Inc.
LandOfFree
Etherlipid-containing multiple lipid liposomes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Etherlipid-containing multiple lipid liposomes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Etherlipid-containing multiple lipid liposomes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-649582